Immuno-Oncology
GPCRs constitute strategic targets mediating immunosuppression. The company exploits its expertise in the field to move forward small molecule and antibody based-assets toward the clinic.
CNS and Rare diseases
With the aim at establishing early partnerships, the company has launched multiple proprietary and collaborative GPCR-based programs in neurology and rare diseases.
-
Discover
mGluR4/7/8 positive allosteric modulator for Parkinson’s disease
-
Discover
NPFFR small molecule antagonist to combat the opioid crisis
-
Discover
Orphan GPCRs for Central Nervous System (CNS) disease area
-
Discover
PAR2 negative allosteric modulator for rare inflammatory diseases
-
Discover
MC4R pharmacochaperone for the treatment of early onset obesity
-
Discover
New GPCRs target identification and validation
Participation portfolio
Over the past years, Domain Therapeutics has taken part in the acceleration of breakthrough innovations coming from academia by contributing to their development into dedicated new companies.
Partnerships
Partnering with us